Tranexamic Acid in Pregnancies With Vaginal Bleeding

Hawler Medical University

Status: Completed

Conditions: Vaginal Bleeding During Pregnancy

Treatments: Drug: Tranexamic Acid

Study type: Interventional

Funder types: Other

Identifiers

NCT03632824

HawlerMU 27.7

Details and patient eligibility

About

Tranexamic acid has been proposed and used for prevention and management of antepartum and postpartum hemorrhage.

Full description

Bleeding during pregnancy is associated with a three- to fourfold increase in perinatal mortality. Hemorrhage in pregnancy is characterized by activation of the fibrinolytic system. Tranexamic acid is a potent pharmaceutical agent that suppresses fibrinolysis, and thus can be used for managing hemorrhage in pregnancy. The FDA's pregnancy category for tranexamic acid is category B. Tranexamic acid has been used to decrease blood loss and treatment of intra partum blood loss in cesarean section also it has been used for prevention and management of postpartum hemorrhage after vaginal bleeding, regardless of whether the bleeding is due to genital tract trauma or other causes.

Enrollment: 139 estimated patients

Sex: Female

Ages: 18 to 42 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• pregnant woman having vaginal bleeding
• Second and third trimester of unknown etiology
• No placenta previa, abruptio placentae, local cervical or vaginal causes for bleeding
• Primigraivid, multiparous and grand multiparous woman
• Accept to participate in the trial

Exclusion criteria

• Hypersensitivity to tranexamic acid
• Women with acquired defective color vision
• History of venous thromboembolism
• Refused to participate

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

139 participants in 2 patient groups, including a placebo group

interventional arm

Experimental group

Description:

Tranexamic acid applied intravenously for 2 days followed by oral tranexamic acid

Treatment:

Drug: Tranexamic Acid

comparative group

Placebo Comparator group

Description:

expectant management, including admission to hospital, ultrasound examination at least twice a week, regular blood coagulation tests, fetal wellbeing , frequent ultrasound performing for placenta location ,betamethasone administration for whom delivery was suspected

Treatment:

Drug: Tranexamic Acid